Close Menu

NEW YORK — Sienna Cancer Diagnostics said on Friday that it has raised approximately A$1.7 million ($1.1 million) through a previously announced private stock placement. 

According to the Melbourne, Australia-based company, it sold 47.3 million shares to institutional and other certain investors at A$.0.35 per share through the private placement. Sienna also plans to offer 72 million new shares to eligible existing shareholders at the same price per share for gross proceeds of A$2.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.